

Pavan Bhargava

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6198875/publications.pdf>

Version: 2024-02-01

56
papers

2,613
citations

218677

26
h-index

197818

49
g-index

62
all docs

62
docs citations

62
times ranked

4105
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2022, 74, 427-436.	5.8	15
2	Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies. <i>Lancet Rheumatology</i> , The, 2022, 4, e247.	3.9	1
3	Response to "Tracking the role of sphingolipids in MS: The dynamic nature of ceramide synthases". <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210840.	3.0	0
4	Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2020-2026.	3.0	4
5	Contribution of B cells to cortical damage in multiple sclerosis. <i>Brain</i> , 2022, 145, 3363-3373.	7.6	15
6	Intermittent calorie restriction alters T cell subsets and metabolic markers in people with multiple sclerosis. <i>EBioMedicine</i> , 2022, 82, 104124.	6.1	29
7	Serum ceramide levels are altered in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1506-1519.	3.0	20
8	Synaptic and complement markers in extracellular vesicles in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 509-518.	3.0	38
9	Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. <i>Brain</i> , 2021, 144, 1396-1408.	7.6	44
10	Exercise leads to metabolic changes associated with improved strength and fatigue in people with MS. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1308-1317.	3.7	6
11	Targeting metabolism to treat multiple sclerosis. <i>Neural Regeneration Research</i> , 2021, 16, 502.	3.0	2
12	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. <i>Cell Reports Medicine</i> , 2021, 2, 100424.	6.5	26
13	Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. <i>EBioMedicine</i> , 2021, 73, 103636.	6.1	85
14	Metabolomics in multiple sclerosis disease course and progression. <i>Multiple Sclerosis Journal</i> , 2020, 26, 591-598.	3.0	36
15	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. <i>Journal of Clinical Investigation</i> , 2020, 130, 3467-3482.	8.2	109
16	Early complement genes are associated with visual system degeneration in multiple sclerosis. <i>Brain</i> , 2019, 142, 2722-2736.	7.6	30
17	Lipidomic characterization of extracellular vesicles in human serum. <i>Journal of Circulating Biomarkers</i> , 2019, 8, 184945441987984.	1.3	56
18	Altered Levels of Toll-Like Receptors in Circulating Extracellular Vesicles in Multiple Sclerosis. <i>Cells</i> , 2019, 8, 1058.	4.1	25

#	ARTICLE	IF	CITATIONS
19	Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 33-45.	3.7	39
20	Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 136-140.	2.0	45
21	Improved Visualization of Cortical Lesions in Multiple Sclerosis Using 7T MP2RAGE. <i>American Journal of Neuroradiology</i> , 2018, 39, 459-466.	2.4	65
22	Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans. <i>Current Eye Research</i> , 2018, 43, 415-423.	1.5	12
23	Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. <i>Science</i> , 2018, 360, 449-453.	12.6	489
24	Dimethyl fumarate treatment alters NK cell function in multiple sclerosis. <i>European Journal of Immunology</i> , 2018, 48, 380-383.	2.9	41
25	Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 173-182.	2.0	29
26	Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1211-1221.	3.7	55
27	Brief Report: Anti- α -Calponin 3 Autoantibodies: A Newly Identified Specificity in Patients With Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1610-1616.	5.6	13
28	Disease-modifying therapies modulate retinal atrophy in multiple sclerosis. <i>Neurology</i> , 2017, 88, 525-532.	1.1	73
29	Dimethyl fumarate alters B cell memory and cytokine production in MS patients. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 351-355.	3.7	54
30	Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. <i>JCI Insight</i> , 2017, 2, .	5.0	79
31	Combined registration and motion correction of longitudinal retinal OCT data. <i>Proceedings of SPIE</i> , 2016, 9784, .	0.8	13
32	An update on the evidence base for peginterferon β 1a in the treatment of relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 483-490.	3.5	7
33	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. <i>Neurology</i> , 2016, 87, 446-446.	1.1	0
34	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. <i>Neurology</i> , 2016, 87, 445-446.	1.1	0
35	Metabolomics in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 451-460.	3.0	49
36	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. <i>Neurology</i> , 2016, 86, 382-390.	1.1	124

#	ARTICLE	IF	CITATIONS
37	Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. <i>Multiple Sclerosis Journal</i> , 2016, 22, 753-760.	3.0	49
38	Outer retinal changes following acute optic neuritis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 362-372.	3.0	53
39	A Unique Case of Intravascular Lymphoma Mimicking Encephalomyeloneuropathy. <i>Neurologist</i> , 2015, 20, 18-21.	0.7	4
40	Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. <i>Annals of Neurology</i> , 2015, 78, 801-813.	5.3	304
41	Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. <i>Multiple Sclerosis International</i> , 2015, 1-10.	0.8	35
42	1,25-Dihydroxyvitamin D3 impairs the differentiation of effector memory T cells in vitro in multiple sclerosis patients and healthy controls. <i>Journal of Neuroimmunology</i> , 2015, 279, 20-24.	2.3	9
43	Longitudinal graph-based segmentation of macular OCT using fundus alignment. <i>Proceedings of SPIE</i> , 2015, 9413, .	0.8	8
44	Familial Transient Global Amnesia. <i>Mayo Clinic Proceedings</i> , 2015, 90, 696-697.	3.0	5
45	Automatic segmentation of microcystic macular edema in OCT. <i>Biomedical Optics Express</i> , 2015, 6, 155.	2.9	60
46	Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. <i>Brain</i> , 2014, 137, 2271-2286.	7.6	128
47	Clinical Reasoning: An unusual cause of transverse myelitis?. <i>Neurology</i> , 2014, 82, e46-50.	1.1	8
48	Right Brain: Humor completes the neurologic examination. <i>Neurology</i> , 2014, 82, e21-2.	1.1	4
49	The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. <i>Contemporary Clinical Trials</i> , 2014, 39, 288-293.	1.8	64
50	Gut Microbiome and Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 492.	4.2	106
51	A Pediatric Case of Painful Legs and Moving Toes Syndrome. <i>Pediatric Neurology</i> , 2013, 49, 298-299.	2.1	4
52	The expanding spectrum of aetiologies causing retinal microcystic macular change. <i>Brain</i> , 2013, 136, 3212-3214.	7.6	20
53	Osteoporosis in ankylosing spondylitis. <i>International Journal of Rheumatic Diseases</i> , 2008, 11, 374-380.	1.9	1
54	Drug compliance after stroke and myocardial infarction: Is complementary medicine an issue?. <i>Neurology India</i> , 2008, 56, 93.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Survival in rhinocerebral mucormycosis: Is iron the key?. Neurology India, 2007, 55, 416.	0.4	1
56	Peptidylarginine Deiminase 2 Autoantibodies Are Linked to Less Severe Disease in Multiple Sclerosis and Post-treatment Lyme Disease. Frontiers in Neurology, 0, 13, .	2.4	5